Nevin Hammam, Doaa Mosad, Amira M Ibrahim, Yousra H Abdel-Fattah, Hany M Aly, Hanan M El-Saadany, Maha Nassr, Abdelhafeez Moshrif, Hanan M Fathi, Samah I Nasef, Faten Ismail, Rawhya R El Shereef, Osman Hammam, Mervat I Abd-Elazeem, Enas A Abdelaleem, Abdelrahman Mohamed Elsayed, Samar Tharwat, Tamer A Gheita
{"title":"在埃及风湿病和肌肉骨骼疾病患者接种COVID-19疫苗的安全性：一项横断面研究","authors":"Nevin Hammam, Doaa Mosad, Amira M Ibrahim, Yousra H Abdel-Fattah, Hany M Aly, Hanan M El-Saadany, Maha Nassr, Abdelhafeez Moshrif, Hanan M Fathi, Samah I Nasef, Faten Ismail, Rawhya R El Shereef, Osman Hammam, Mervat I Abd-Elazeem, Enas A Abdelaleem, Abdelrahman Mohamed Elsayed, Samar Tharwat, Tamer A Gheita","doi":"10.5001/omj.2024.107","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the incidence and associated risk factors of adverse events following COVID-19 vaccination in patients with inflammatory and non-inflammatory rheumatic and musculoskeletal diseases (I-RMD and NI-RMD, respectively).</p><p><strong>Methods: </strong>The Egyptian College of Rheumatology COVID-19 Study Group investigated physician-reported data (ECR-VaXurvey3) of RMD patients vaccinated against COVID-19 from December 2021 to June 2022, including their demographics, vaccination type, RMD diagnosis, treatments, post-vaccine flares, and other adverse events. The control group consisted of healthy, vaccinated individuals.</p><p><strong>Results: </strong>The ECR-VaXurvey3 included 890 vaccinated RMD patients, predominantly women (73.3%) with a mean age of 44.4 ± 12.1 years, and 172 controls. The RMD group comprised 816 (91.7%) with I-RMD and 74 (8.3%) with NI-RMD. The frequency of adverse events was comparable between the RMD and control groups. In RMD patients, injection site pain (59.9%) was the most reported adverse event. Post-vaccination COVID-19 infections and disease flares were reported in 2.9% and 12.1% of I-RMD patients and in 8.1% and 9.5% of NI-RMD patients (<i>p =</i> 0.018 and <i>p =</i> 0.497, respectively). The severity of prior COVID-19 infection (odds ratio (OR) = 2.4, 95% CI: 1.0-5.8; <i>p =</i> 0.040) and azathioprine use (OR = 2.6, 95% CI: 1.1-5.9; <i>p =</i> 0.024) were associated with higher post-vaccine adverse events, while biologic use was associated with fewer adverse events (OR = 0.5, 95% CI: 0.3-0.8; p = 0.010).</p><p><strong>Conclusions: </strong>Adverse events following COVID-19 vaccinations in patients with RMD are comparable to controls.</p>","PeriodicalId":19667,"journal":{"name":"Oman Medical Journal","volume":"39 5","pages":"e676"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973885/pdf/","citationCount":"0","resultStr":"{\"title\":\"Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt.\",\"authors\":\"Nevin Hammam, Doaa Mosad, Amira M Ibrahim, Yousra H Abdel-Fattah, Hany M Aly, Hanan M El-Saadany, Maha Nassr, Abdelhafeez Moshrif, Hanan M Fathi, Samah I Nasef, Faten Ismail, Rawhya R El Shereef, Osman Hammam, Mervat I Abd-Elazeem, Enas A Abdelaleem, Abdelrahman Mohamed Elsayed, Samar Tharwat, Tamer A Gheita\",\"doi\":\"10.5001/omj.2024.107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To investigate the incidence and associated risk factors of adverse events following COVID-19 vaccination in patients with inflammatory and non-inflammatory rheumatic and musculoskeletal diseases (I-RMD and NI-RMD, respectively).</p><p><strong>Methods: </strong>The Egyptian College of Rheumatology COVID-19 Study Group investigated physician-reported data (ECR-VaXurvey3) of RMD patients vaccinated against COVID-19 from December 2021 to June 2022, including their demographics, vaccination type, RMD diagnosis, treatments, post-vaccine flares, and other adverse events. The control group consisted of healthy, vaccinated individuals.</p><p><strong>Results: </strong>The ECR-VaXurvey3 included 890 vaccinated RMD patients, predominantly women (73.3%) with a mean age of 44.4 ± 12.1 years, and 172 controls. The RMD group comprised 816 (91.7%) with I-RMD and 74 (8.3%) with NI-RMD. The frequency of adverse events was comparable between the RMD and control groups. In RMD patients, injection site pain (59.9%) was the most reported adverse event. Post-vaccination COVID-19 infections and disease flares were reported in 2.9% and 12.1% of I-RMD patients and in 8.1% and 9.5% of NI-RMD patients (<i>p =</i> 0.018 and <i>p =</i> 0.497, respectively). The severity of prior COVID-19 infection (odds ratio (OR) = 2.4, 95% CI: 1.0-5.8; <i>p =</i> 0.040) and azathioprine use (OR = 2.6, 95% CI: 1.1-5.9; <i>p =</i> 0.024) were associated with higher post-vaccine adverse events, while biologic use was associated with fewer adverse events (OR = 0.5, 95% CI: 0.3-0.8; p = 0.010).</p><p><strong>Conclusions: </strong>Adverse events following COVID-19 vaccinations in patients with RMD are comparable to controls.</p>\",\"PeriodicalId\":19667,\"journal\":{\"name\":\"Oman Medical Journal\",\"volume\":\"39 5\",\"pages\":\"e676\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973885/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oman Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5001/omj.2024.107\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oman Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5001/omj.2024.107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Safety of COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: A Cross-sectional Study in Egypt.
Objectives: To investigate the incidence and associated risk factors of adverse events following COVID-19 vaccination in patients with inflammatory and non-inflammatory rheumatic and musculoskeletal diseases (I-RMD and NI-RMD, respectively).
Methods: The Egyptian College of Rheumatology COVID-19 Study Group investigated physician-reported data (ECR-VaXurvey3) of RMD patients vaccinated against COVID-19 from December 2021 to June 2022, including their demographics, vaccination type, RMD diagnosis, treatments, post-vaccine flares, and other adverse events. The control group consisted of healthy, vaccinated individuals.
Results: The ECR-VaXurvey3 included 890 vaccinated RMD patients, predominantly women (73.3%) with a mean age of 44.4 ± 12.1 years, and 172 controls. The RMD group comprised 816 (91.7%) with I-RMD and 74 (8.3%) with NI-RMD. The frequency of adverse events was comparable between the RMD and control groups. In RMD patients, injection site pain (59.9%) was the most reported adverse event. Post-vaccination COVID-19 infections and disease flares were reported in 2.9% and 12.1% of I-RMD patients and in 8.1% and 9.5% of NI-RMD patients (p = 0.018 and p = 0.497, respectively). The severity of prior COVID-19 infection (odds ratio (OR) = 2.4, 95% CI: 1.0-5.8; p = 0.040) and azathioprine use (OR = 2.6, 95% CI: 1.1-5.9; p = 0.024) were associated with higher post-vaccine adverse events, while biologic use was associated with fewer adverse events (OR = 0.5, 95% CI: 0.3-0.8; p = 0.010).
Conclusions: Adverse events following COVID-19 vaccinations in patients with RMD are comparable to controls.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
